Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Quantification of pulmonary disease activity in sarcoidosis measured with 18F-FDG PET/CT: SUVmax versus total lung glycolysis.

Schimmelpennink MC, Vorselaars ADM, Veltkamp M, Keijsers RGM.

EJNMMI Res. 2019 Jun 13;9(1):54. doi: 10.1186/s13550-019-0505-x.

2.

Cyclophosphamide in steroid refractory unclassifiable idiopathic interstitial pneumonia and interstitial pneumonia with autoimmune features (IPAF).

Wiertz IA, van Moorsel CHM, Vorselaars ADM, Quanjel MJR, Grutters JC.

Eur Respir J. 2018 Apr 19;51(4). pii: 1702519. doi: 10.1183/13993003.02519-2017. Print 2018 Apr. No abstract available.

PMID:
29496758
3.

Efficacy and safety of infliximab biosimilar Inflectra® in severe sarcoidosis.

Schimmelpennink MC, Vorselaars ADM, van Beek FT, Crommelin HA, Deneer VHM, Keijsers RGM, Veltkamp M.

Respir Med. 2018 May;138S:S7-S13. doi: 10.1016/j.rmed.2018.02.009. Epub 2018 Feb 19.

PMID:
29496351
4.

Unfavourable outcome of glucocorticoid treatment in suspected idiopathic pulmonary fibrosis.

Wiertz IA, Wuyts WA, van Moorsel CHM, Vorselaars ADM, van Es HW, van Oosterhout MFM, Grutters JC.

Respirology. 2018 Mar;23(3):311-317. doi: 10.1111/resp.13230. Epub 2017 Dec 5.

5.

Can intermediate monocytes predict response to infliximab therapy in sarcoidosis?

Hijdra D, Vorselaars AD, Crommelin HA, van Moorsel CH, Meek B, Claessen AM, Rijkers GT, Grutters JC.

Eur Respir J. 2016 Oct;48(4):1242-1245. doi: 10.1183/13993003.00709-2016. Epub 2016 Jul 7. No abstract available.

6.

Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab.

Crommelin HA, van der Burg LM, Vorselaars AD, Drent M, van Moorsel CH, Rijkers GT, Deneer VH, Grutters JC.

Respir Med. 2016 Jun;115:72-7. doi: 10.1016/j.rmed.2016.04.011. Epub 2016 Apr 23.

7.

Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis.

Verwoerd A, Hijdra D, Vorselaars AD, Crommelin HA, van Moorsel CH, Grutters JC, Claessen AM.

Clin Exp Immunol. 2016 Aug;185(2):263-70. doi: 10.1111/cei.12808. Epub 2016 Jul 12.

8.

Managing FDG PET-positive sarcoidosis: "a riddle wrapped in a mystery inside an enigma".

Vorselaars AD, Crommelin HA, van Moorsel CH, Grutters JC.

Eur Respir J. 2016 Jan;47(1):347-8. doi: 10.1183/13993003.01438-2015. No abstract available.

9.

Is there evidence for anti-TNF drugs in joint involvement in sarcoidosis?

Crommelin HA, Vorselaars AD, van Moorsel CH, Korenromp IH, Deneer VH, Grutters JC.

Immunotherapy. 2015;7(6):601. doi: 10.2217/imt.15.25. Epub 2015 Jun 22. No abstract available.

10.

Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis.

Vorselaars AD, Crommelin HA, Deneer VH, Meek B, Claessen AM, Keijsers RG, van Moorsel CH, Grutters JC.

Eur Respir J. 2015 Jul;46(1):175-85. doi: 10.1183/09031936.00227014. Epub 2015 Apr 30.

11.

Discrepant elevation of sIL-2R levels in sarcoidosis patients with renal insufficiency.

Verwoerd A, Vorselaars AD, van Moorsel CH, Bos WJ, van Velzen-Blad H, Grutters JC.

Eur Respir J. 2015 Jul;46(1):277-80. doi: 10.1183/09031936.00005315. Epub 2015 Mar 5. No abstract available.

12.

ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy.

Vorselaars AD, van Moorsel CH, Zanen P, Ruven HJ, Claessen AM, van Velzen-Blad H, Grutters JC.

Respir Med. 2015 Feb;109(2):279-85. doi: 10.1016/j.rmed.2014.11.009. Epub 2014 Nov 29.

13.

Anti-TNF therapeutics for the treatment of sarcoidosis.

Crommelin HA, Vorselaars AD, van Moorsel CH, Korenromp IH, Deneer VH, Grutters JC.

Immunotherapy. 2014;6(10):1127-43. doi: 10.2217/imt.14.65. Review.

PMID:
25428650
14.

Cytotoxic agents in sarcoidosis: which one should we choose?

Vorselaars AD, Cremers JP, Grutters JC, Drent M.

Curr Opin Pulm Med. 2014 Sep;20(5):479-87. doi: 10.1097/MCP.0000000000000078. Review.

PMID:
25046427
15.

Phenotypic characterization of human intermediate monocytes.

Hijdra D, Vorselaars AD, Grutters JC, Claessen AM, Rijkers GT.

Front Immunol. 2013 Oct 22;4:339. doi: 10.3389/fimmu.2013.00339. eCollection 2013. No abstract available.

16.

Current therapy in sarcoidosis, the role of existing drugs and future medicine.

Vorselaars AD, van Moorsel CH, Deneer VH, Grutters JC.

Inflamm Allergy Drug Targets. 2013 Dec;12(6):369-77. Review.

PMID:
24151828
17.

Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis.

Vorselaars AD, Verwoerd A, van Moorsel CH, Keijsers RG, Rijkers GT, Grutters JC.

Eur Respir J. 2014 Feb;43(2):602-9. doi: 10.1183/09031936.00055213. Epub 2013 Aug 29.

18.

Antinuclear antibodies do not predict anti-infliximab antibody induction in sarcoidosis.

Vorselaars AD, Hijdra D, van Moorsel CH, Claessen AM, Grutters JC.

J Am Acad Dermatol. 2013 Aug;69(2):312-4. doi: 10.1016/j.jaad.2012.08.048. No abstract available.

PMID:
23866866
19.

Bilateral Vocal Cord Carcinoma in a Sarcoidosis Patient during Infliximab Therapy.

Vorselaars AD, Sjögren EV, van Moorsel CH, Grutters JC.

Case Rep Pulmonol. 2013;2013:308092. doi: 10.1155/2013/308092. Epub 2013 May 15.

20.

Influence of repeated maximal exercise testing on biomarkers and fatigue in sarcoidosis.

Braam AW, de Haan SN, Vorselaars AD, Rijkers GT, Grutters JC, van den Elshout FJ, Korenromp IH.

Brain Behav Immun. 2013 Oct;33:57-64. doi: 10.1016/j.bbi.2013.05.006. Epub 2013 May 29.

PMID:
23727274
21.

Methotrexate vs azathioprine in second-line therapy of sarcoidosis.

Vorselaars ADM, Wuyts WA, Vorselaars VMM, Zanen P, Deneer VHM, Veltkamp M, Thomeer M, van Moorsel CHM, Grutters JC.

Chest. 2013 Sep;144(3):805-812. doi: 10.1378/chest.12-1728.

PMID:
23538719
22.

Earlobe sarcoidosis.

Vorselaars AD, Keijsers RG, Grutters JC.

Sarcoidosis Vasc Diffuse Lung Dis. 2012 Mar;29(1):55-7.

PMID:
23311125
23.

Differential expression of TNFR1 (CD120a) and TNFR2 (CD120b) on subpopulations of human monocytes.

Hijdra D, Vorselaars AD, Grutters JC, Claessen AM, Rijkers GT.

J Inflamm (Lond). 2012 Oct 5;9(1):38. doi: 10.1186/1476-9255-9-38.

24.

Increased number of pulmonary embolisms in sarcoidosis patients.

Vorselaars ADM, Snijder RJ, Grutters JC.

Chest. 2012 Mar;141(3):826-827. doi: 10.1378/chest.11-2514. No abstract available.

PMID:
22396572
25.

Type D personality and cardiovascular function in daily life of people without documented cardiovascular disease.

Nyklíček I, Vorselaars A, Denollet J.

Int J Psychophysiol. 2011 May;80(2):139-42. doi: 10.1016/j.ijpsycho.2011.02.014. Epub 2011 Feb 26.

PMID:
21362446
26.

Vitamin K deficiency bleeding in cholestatic infants with alpha-1-antitrypsin deficiency.

van Hasselt PM, Kok K, Vorselaars AD, van Vlerken L, Nieuwenhuys E, de Koning TJ, de Vries RA, Houwen RH.

Arch Dis Child Fetal Neonatal Ed. 2009 Nov;94(6):F456-60. doi: 10.1136/adc.2008.148239. Epub 2009 May 3.

PMID:
19414430

Supplemental Content

Loading ...
Support Center